It began with huge advancements in the field of genomics, which in turn created the opportunity for tailoring treatments to individuals, or subsets of the population, such that today we are seeing the first personalised medicines emerging on the healthcare market. Research into the identification of molecular markers towards disease predisposition and progression has led to a burgeoning manufacturing sector producing biomarkers and general diagnostics. The pharmaceutical market quickly realised the benefit of such biomarkers in producing ‘companion diagnostics’, which are developed alongside the therapeutic to enable better decision-making about the development and use of a potential drug therapy.
According to the report Personalized Medicine Market Analysis by RNCOS, published in May, the US is the lead market for personalised medicine and is forecast to grow at a compound annual growth rate (CAGR) of around 9.5% during 2012-2017. Such figures become meaningful only when broken down into more specific sectors, but with such rapidly developing sectors – and terminology – this can be quite complex and market reports tend to focus on different but often overlapping aspects of biomarkers and companion diagnostics.
According to Companiesandmarkets.com, the global biomarkers market reached US$13bn in 2011. The majority of revenue was generated through the application of biomarkers in the discovery, testing and prescription of oncology therapeutics, with other leading therapeutics areas being central nervous system (CNS) and cardiovascular system (CVS) disorders.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.